Passer au français
class members

Ozempic, Wegovy, Mounjaro and Other GLP-1 Agonists Side Effects Canadian Class Action

Investigation
Join This Class Action



CONSUMER LAW GROUP is investigating a Canada-wide class action lawsuit against Novo Nordisk Canada Inc. and Eli Lilly Canada Inc. in relation to their weight-loss and diabetes medications:

• Ozempic (semaglutide) [2018]
• Rybelsus (semaglutide) [2020]
• Wegovy (semaglutide) [2021]
• Mounjaro (tirzepatide) [2022]
• Trulicity (dulaglutide) [2022]
• Saxenda (liraglutide) [2015]
• Victoza (tirzepatide) [2010]

The proposed class action is based on allegations that these drugs have improperly disclosed or failed to warn about certain side effects such as:

- Gastroparesis / stomach paralysis
- Gastric statis
- Ileus
- Gastric obstruction
- Intestinal obstruction

These medical conditions often lead to hospitalization, surgery, and vomiting for extended lengths of time.

Glucagon-Like Peptide-1 (GLP-1) agonists are a class of medications that can help lower blood sugar levels and promote weight loss. GLP-1 agonist medications work by mimicking a naturally occurring GLP-1 hormone. In medical terms, an agonist is a manufactured substance that attaches to a cell receptor and causes the same action as the naturally occurring substance. One way in which these drugs work is by stimulating insulin production and reducing glucose production in the liver helping to lower blood sugar levels.

There have been several published studies since as least 2018 that expose the above risks associated with these medications:

• Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery, July 2018, Modi et al.
• Liraglutide-induced Acute Gastroparesis, December 2018, Rai et al.
• Diabetic Gastroparesis: A Review, August 2020, Young et al.
• Gastroparesis With the Initiation of Liraglutide: A Case Report, November 2020, Almustanyir et al.
• Medication-Induced Gastroparesis: A Case Report, January 2021, Kalas et al.
• Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes, January 2022, Faillie et al.
• Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide, July 2022, Ishihara et al.
• Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery, January 2023, Preda et al.
• Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report, March 2023, Klein et al.
• Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report, July 2023, Fujino et al.
• Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss, October 2023, Sodhi et al.

Similar lawsuits are ongoing in the United States:

- Complaint – August 2, 2023 (Louisiana)
- Complaint – September 19, 2023 (Pennsylvania)
- Complaint – September 29, 2023 (Louisiana)

If you or someone you know has taken Ozempic, Rybelsus, Wegovy, Mounjaro, Trulicity, Saxenda, or Victoza and has suffered from gastroparesis / stomach paralysis, gastric statis, ileus, gastric obstruction, intestinal obstruction causing hospitalization, surgery, or vomiting for extended lengths of time and you wish to receive more information on potential compensation or to be kept advised of the status of the Ozempic, Wegovy, Mounjaro and Other GLP-1 Agonists Side Effects Canadian Class Action litigation or any resulting compensation from this lawsuit in Canada, Ontario, or Quebec, please provide your contact information to our law firm by using the form below.

IF YOU WISH TO JOIN THE CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE FORM BELOW. Please note that providing your information creates no financial obligation for you. You are not charged any fee or cost for joining this class action. Our law firm is paid a contingency fee from the compensation recovered, only if the class action is successful. All information contained in this transmission is confidential and Consumer Law Group agrees to protect this information against unauthorized use, publication or disclosure.


Join This Class Action
 
Ozempic, Wegovy, Mounjaro and Other GLP-1 Agonists Side Effects Canadian Class Action
First Name:
Last Name:
Email:
Confirm Email:
Address:
City:
Province:
Country:
Postal Code:
Home phone:
Work phone:
Cell phone:
Fax:
Damages or Symptoms experienced:
Other Comments:
Please add my email address to the CLG.org mailing list to receive timely emails containing information on this class action and information on other CLG.org class actions. Information on class actions includes new class action announcements, relevant class action information updates, and class action payout information.

Disclaimer: The Consumer Law Group website is not intended to create an attorney-client relationship between you and the firm. By submitting your information to us, you are not creating an attorney-client relationship with the firm, although the information will be kept confidential. An attorney-client relationship may be formed only after we check for conflicts of interest and the firm and you sign a mandate agreement. The firm may contact you about your legal claim to discuss representation options. Because of the volume of e-mails, we cannot promise to respond to every submission.

In any class action lawsuit, it is the court that approves who will be eligible for participation in the class. If you feel you may qualify for damages or remedies that might be awarded in this class action litigation, we request you fill out the above form to help us determine if you are a legitimate member of the class or to make sure you get any court mailings about the case. However, the return of the above form does not guarantee you any type of compensation.


Enter the number above




Post a Comment

Time is of the essence for this program!
Canadian Vaccine Injury Compensation Program